Patent 11802269 was granted and assigned to Poseida Therapeutics on October, 2023 by the United States Patent and Trademark Office.
The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.